Catalyst
Slingshot members are tracking this event:
Alexion's (ALXN) ALXN1210 Granted Orphan Drug Designation by FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 06, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Alxn1210, Orphan Drug Designation, Fda, Paroxysmal Nocturnal Hemoglobinuria, Pnh
